Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.45 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324271 | 1.00 | GFPT1 (0.45) | GFPT1GRIK1GRIK2DDAH1CASP1 | |
| Hydrochloric Acid SCHEMBL31496724 | 0.98 | GFPT1 (0.44) | GFPT1GRIK1GRIK2DDAH1CASP1 | |
| SCHEMBL16446798 | 0.89 | GFPT1 (0.40) | GFPT1GRIK1GRIK2DDAH1CASP1 | |
| SCHEMBL15746590 | 0.84 | DDAH1 (0.39) | GFPT1GRIK1GRIK2DDAH1CASP1 | |
| SCHEMBL24185361 | 0.83 | DDAH1 (0.46) | GRIK1GRIK2DDAH1CASP1MAPT | |
| SCHEMBL7194971 | 0.81 | DDAH1 (0.57) | GRIK1GRIK2DDAH1CASP1MEN1 | |
| SCHEMBL22281180 | 0.81 | DDAH1 (0.57) | GRIK1GRIK2DDAH1CASP1MEN1 | |
| SCHEMBL28297586 | 0.81 | DDAH1 (0.57) | GRIK1GRIK2DDAH1CASP1MEN1 | |
| SCHEMBL18159716 | 0.81 | TDP1 (0.39) | CASP1MAPTCACNA1BAPBA1MEN1 | |
| SCHEMBL1700571 | 0.80 | ARG1 (0.37) | GRIK1GRIK2DDAH1CASP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| CN-113226375-A | Methods and compositions | 英国研究与创新署 | 2021-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GFPT1 638/4885GRIK1 2914/4885GRIK2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.